PTK2 and ovarian cancer: Once we characterized ovarian cancer cell lines (Fig. S1, Tables S3 and S4 in File S1), we treated the cancer cell lines with the FAK inhibitors, PF-573,228 (PF228) and PF-562,271 (PF271) (Fig. 2A).